Anlon Healthcare

Anlon Healthcare Limited - IPO

MAINBOARD

Anlon Healthcare IPO Details

Open Date
-
Close Date
-
Listing Date
-
Issue Price
₹0 - ₹0
Face Value
₹10 per share
Lot Size
0
GMP
₹0
Issue Type
IPO
Listing On
NSE, BSE
Type
Book Built Issue
Share holding pre issue
39851500
Share holding post issue
53851500
Total Issue Size
1,40,00,000 shares (aggregating up to ₹0.00 Cr)
Fresh Issue
1,40,00,000 shares (aggregating up to ₹0.00 Cr)
Offer for Sale
-
DRHP Status
Filed With SEBI

Anlon Healthcare IPO Lot Size

ApplicationLotsSharesAmount
To be announced

Anlon Healthcare IPO Reservation

Promoter Holding

Pre Issue:70.26%
Post Issue:-
Promoter Names:
Punitkumar R. rasadia, Meet Atulkumar Vachhani, Mamata punitkumar Rasadia

Documents

Anlon Healthcare IPO Valuations

ROE:0.98%
ROCE:16.29%
DEBT/EQUITY:3.55
RONW:45.92%
PAT MARGIN:14.50

Anlon Healthcare Limited Financial Information

Period Ended31 Jan 202531 Mar 202431 Mar 202331 Mar 2022
Assets160.96128111.5584.97
Revenue77.3766.69113.1257.54
Profit After Tax11.969.665.82-0.11
Net Worth71.8621.037.371.55
Reserves and Surplus32.015.03-4.63-10.24
Total Borrowing62.3974.5666.3960.32
Amount in ₹ Crore

About Anlon Healthcare IPO

Incorporated in 2013, Anlon Healthcare Limited is a chemical manufacturing company engaged in manufacturing of Pharma Intermediates and active pharmaceutical ingredients (APIs).

The company manufactures high-purity pharmaceutical intermediates (for API production) and active pharmaceutical ingredients (used in formulations for medicines, nutraceuticals, personal care, and animal health products).

The company offers pharmaceutical intermediates, APIs for medicines, nutraceuticals, personal care, and veterinary products, all manufactured following Indian and international pharmacopeia standards like IP, BP, EP, JP, and USP.

In addition to manufacturing Pharma Intermediates and APIs to global standards, the company now offers custom manufacturing for complex chemicals, exceeding purity standards and reducing impurities to meet specific customer needs.

The company has received Drug Master File (DMF) approval from ANVISA, NMPA, and PMDA for loxoprofen sodium dihydrate and loxoprofen acid APIs. The company has filed 21 DMFs with global authorities and is in the process of filing for Ketoprofen and Dexketoprofen Trometamol approvals.

The company’s portfolio includes 65 commercialized products, 28 at the pilot stage, and 49 in laboratory testing.

The company ensures product quality through rigorous testing, analysis, and process improvements. Supported by four labs, the 34-member team, including 24 science graduates, ensures products meet customer and industry standards.

Products:

  • Pharma Intermediates:Cyanoethylbe nzoic acid, Ketonitrile and Methyldeslor atadine, these serve as a key starting material or as an advance intermediate for manufacturing of APIs.
  • Active Pharmaceutical Ingredients: The company’s APIs are key components in pharmaceutical products, delivering therapeutic effects. They are used in formulations like tablets, capsules, ointments, syrups, and in nutraceuticals, personal care, and veterinary products.

As of January 31, 2025, the company had 105 employees (excluding trainees) and 8 contract workers.

Strength Of Anlon Healthcare IPO

To be announced

Risk Of Anlon Healthcare IPO

To be announced

Objectives Anlon Healthcare IPO

1. Funding capital expenditure requirements for Proposed Expansion

2. Full or part repayment and/or prepayment of certain outstanding secured borrowingssecured borrowing (term loan)availed by the Company

3. Funding the working capital requirements of the Company

4. General corporate purposes

Company Contact Details

Anlon Healthcare Limited
101/102, Silvercoin Complex,
Opp.Crystal Mall,
Kalawad Road,
Phone: +91 281 2562538
Email: cs@anloncro.com
Website: http://www.anlon.in/

Registrar Contact Details

Name: Kfin Technologies Limited
Phone: +91-40-67162222

Lead Mangers

  1. Interactive Financial Services Ltd

Comments